Pricing Log in Create free account

Novavax, Inc. (NVAX) vs SELLAS Life Sciences Group, Inc. (SLS)

Novavax, Inc. and SELLAS Life Sciences Group, Inc. are both Biotechnology companies. Novavax, Inc. and SELLAS Life Sciences Group, Inc. are of similar size ($1.6B and $1.6B). SELLAS Life Sciences Group, Inc. has the higher net margin (0.00% vs −18.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Novavax, Inc. leads on 7 and SELLAS Life Sciences Group, Inc. on 6.

Valuation

Metric NVAX SLS Biotechnology median
P/E n/m n/m 10.60
P/S 4.31 149.37 9.40
P/B n/m 11.39 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 3.28 136.22 9.02
Earnings yield (4.28%) (2.53%) (32.88%)
Free cash flow yield (13.87%) (2.45%) (23.13%)

Profitability

Metric NVAX SLS Biotechnology median
Gross margin 78.01% 0.00% 68.51%
Operating margin (21.23%) 0.00% 0.00%
Net margin (18.64%) 0.00% 0.00%
Free cash flow margin (58.05%) 0.00% 0.00%
Return on equity 41.08% (39.63%) (51.96%)
Return on assets (7.42%) (36.54%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric NVAX SLS Biotechnology median
Revenue growth (TTM) (61.33%) — 6.76%
EPS growth (last fiscal year) 309.76% 50.00% 29.88%
Revenue growth, 5-year CAGR 18.76% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NVAX SLS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.15 18.83 4.97
Net debt to EBITDA (1.04) 2.54 1.01

Dividend

Metric NVAX SLS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric NVAX SLS Biotechnology median
Market cap 1.61b 1.59b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack